Y.RamachandranA.DuanL.SchaichM
Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al

Overall, Semaglutide has shown promise in managing a variety of inflammation-based causes: reduced cardiovascular and COVID-19 death [16, 17, 19] improved PCOS-related symptoms, reduced insulin resistance, demonstrated renoprotective effects in diabetics and chronic kidney disease (CKD), improves liver enzyme levels, steatosis, and stiffness, aids in managing Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, reduces major adverse cardiovascular events, improved heart failure symptoms, reduced physical limitations in diabetics, benefits in cognitive disorders, including Alzheimers disease, Parkinsons disease, and vascular dementia decrease risk of hypothyroidism are safe and effective for Multiple Sclerosis (MS, an autoimmune disease) [14] [31][26] promise neuroprotection in MS [15] increase Vitamin D values [14] exerted protective effects against the risk of various types of cancer (ongoing human studies) How
%20covered%20by%20insurance%3F)
THE MATH THAT MAKES YOU STOP AND THINK Neurodevelopmental disorder rate: 1 in 36 children 3.6 million births per year in the USA 1:36 = 100,000 children diagnosed annually 65% of pregnant women take acetaminophen (2.3 million women annually) At least 10% have compromised glutathione (PCOS, IVF, poor diet, chemical exposure, genetics) Thats 200,000+ pregnancies per year where acetaminophen depletes the molecule needed for healthy brain development If even half of those 200,000 vulnerable pregnancies result in developmental issues, youve accounted for a significant portion of the affected population
Should I ask my primary care doctor for her thoughts